Alvotech’s proposed merger with a blank cheque company is set to complete next week, creating a new, publicly listed pureplay biosimilars company with an implied initial enterprise value of approximately $2.25bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?